Electrolyte imbalance, development of an acidotic state, and central nervous system effects might be expected to occur in the case of an overdose.
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Duloxetine | The risk or severity of orthostatic hypotension and syncope can be increased when Methazolamide is combined with Duloxetine. |
| Levodopa | The risk or severity of hypotension and orthostatic hypotension can be increased when Methazolamide is combined with Levodopa. |
| Risperidone | Methazolamide may increase the hypotensive activities of Risperidone. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Methazolamide is combined with Mecamylamine. |
| Pentolinium | The risk or severity of adverse effects can be increased when Methazolamide is combined with Pentolinium. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Methazolamide is combined with Trimethaphan. |
| Hexamethonium | The risk or severity of adverse effects can be increased when Methazolamide is combined with Hexamethonium. |
| Nicotine | The risk or severity of adverse effects can be increased when Methazolamide is combined with Nicotine. |
| Cyclopentamine | The risk or severity of adverse effects can be increased when Methazolamide is combined with Cyclopentamine. |
| Flecainide | The excretion of Flecainide can be decreased when combined with Methazolamide. |
| Memantine | The excretion of Memantine can be decreased when combined with Methazolamide. |
| Quinine | The excretion of Quinine can be decreased when combined with Methazolamide. |
| Quinidine | The excretion of Quinidine can be decreased when combined with Methazolamide. |
| Methotrexate | The protein binding of Methotrexate can be increased when combined with Methazolamide. |
| Lithium hydroxide | The excretion of Lithium hydroxide can be increased when combined with Methazolamide. |
| Lithium citrate | The excretion of Lithium citrate can be increased when combined with Methazolamide. |
| Metformin | The risk or severity of lactic acidosis can be increased when Methazolamide is combined with Metformin. |
| Aripiprazole | Aripiprazole may increase the hypotensive activities of Methazolamide. |
| Aripiprazole lauroxil | Aripiprazole lauroxil may increase the hypotensive activities of Methazolamide. |
| Nicorandil | Nicorandil may increase the hypotensive activities of Methazolamide. |
| Dexketoprofen | The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Methazolamide. |
| Ketoprofen | The risk or severity of adverse effects can be increased when Ketoprofen is combined with Methazolamide. |
| Methenamine | The serum concentration of the active metabolites of Methenamine can be reduced when Methenamine is used in combination with Methazolamide resulting in a loss in efficacy. |
| Cyclosporine | The risk or severity of renal failure can be increased when Methazolamide is combined with Cyclosporine. |
| Triethylenetetramine | The excretion of Triethylenetetramine can be increased when combined with Methazolamide. |
| Linezolid | Linezolid may increase the orthostatic hypotensive activities of Methazolamide. |
| Furazolidone | Furazolidone may increase the orthostatic hypotensive activities of Methazolamide. |
| Procaine | Procaine may increase the orthostatic hypotensive activities of Methazolamide. |
| Tranylcypromine | Tranylcypromine may increase the orthostatic hypotensive activities of Methazolamide. |
| Phenelzine | Phenelzine may increase the orthostatic hypotensive activities of Methazolamide. |
| Minaprine | Minaprine may increase the orthostatic hypotensive activities of Methazolamide. |
| Selegiline | Selegiline may increase the orthostatic hypotensive activities of Methazolamide. |
| Procarbazine | Procarbazine may increase the orthostatic hypotensive activities of Methazolamide. |
| Moclobemide | Moclobemide may increase the orthostatic hypotensive activities of Methazolamide. |
| Isocarboxazid | Isocarboxazid may increase the orthostatic hypotensive activities of Methazolamide. |
| Rasagiline | Rasagiline may increase the orthostatic hypotensive activities of Methazolamide. |
| Pargyline | Pargyline may increase the orthostatic hypotensive activities of Methazolamide. |
| Clorgiline | Clorgiline may increase the orthostatic hypotensive activities of Methazolamide. |
| Iproniazid | Iproniazid may increase the orthostatic hypotensive activities of Methazolamide. |
| Nialamide | Nialamide may increase the orthostatic hypotensive activities of Methazolamide. |
| Safinamide | Safinamide may increase the orthostatic hypotensive activities of Methazolamide. |
| 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Methazolamide. |
| Methylene blue | Methylene blue may increase the orthostatic hypotensive activities of Methazolamide. |
| Hydracarbazine | Hydracarbazine may increase the orthostatic hypotensive activities of Methazolamide. |
| Pirlindole | Pirlindole may increase the orthostatic hypotensive activities of Methazolamide. |
| Toloxatone | Toloxatone may increase the orthostatic hypotensive activities of Methazolamide. |
| Benmoxin | Benmoxin may increase the orthostatic hypotensive activities of Methazolamide. |
| Mebanazine | Mebanazine may increase the orthostatic hypotensive activities of Methazolamide. |
| Octamoxin | Octamoxin may increase the orthostatic hypotensive activities of Methazolamide. |
| Pheniprazine | Pheniprazine may increase the orthostatic hypotensive activities of Methazolamide. |
| Phenoxypropazine | Phenoxypropazine may increase the orthostatic hypotensive activities of Methazolamide. |
| Pivhydrazine | Pivhydrazine may increase the orthostatic hypotensive activities of Methazolamide. |
| Safrazine | Safrazine may increase the orthostatic hypotensive activities of Methazolamide. |
| Caroxazone | Caroxazone may increase the orthostatic hypotensive activities of Methazolamide. |
| Harmaline | Harmaline may increase the orthostatic hypotensive activities of Methazolamide. |
| Brofaromine | Brofaromine may increase the orthostatic hypotensive activities of Methazolamide. |
| Butalbital | Butalbital may increase the hypotensive activities of Methazolamide. |
| Pentobarbital | Pentobarbital may increase the hypotensive activities of Methazolamide. |
| Secobarbital | Secobarbital may increase the hypotensive activities of Methazolamide. |
| Methohexital | Methohexital may increase the hypotensive activities of Methazolamide. |
| Primidone | Primidone may increase the hypotensive activities of Methazolamide. |
| Methylphenobarbital | Methylphenobarbital may increase the hypotensive activities of Methazolamide. |
| Thiamylal | Thiamylal may increase the hypotensive activities of Methazolamide. |
| Amobarbital | Amobarbital may increase the hypotensive activities of Methazolamide. |
| Hexobarbital | Hexobarbital may increase the hypotensive activities of Methazolamide. |
| Barbital | Barbital may increase the hypotensive activities of Methazolamide. |
| Barbexaclone | Barbexaclone may increase the hypotensive activities of Methazolamide. |
| Thiopental | Thiopental may increase the hypotensive activities of Methazolamide. |
| Phenobarbital | Phenobarbital may increase the hypotensive activities of Methazolamide. |
| Aminosalicylic acid | The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Methazolamide. |
| Mesalazine | The risk or severity of adverse effects can be increased when Mesalazine is combined with Methazolamide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Methazolamide. |
| Diflunisal | The risk or severity of adverse effects can be increased when Diflunisal is combined with Methazolamide. |
| Salicylic acid | The risk or severity of adverse effects can be increased when Salicylic acid is combined with Methazolamide. |
| Balsalazide | The risk or severity of adverse effects can be increased when Balsalazide is combined with Methazolamide. |
| Olsalazine | The risk or severity of adverse effects can be increased when Olsalazine is combined with Methazolamide. |
| Bismuth subsalicylate | The risk or severity of adverse effects can be increased when Bismuth subsalicylate is combined with Methazolamide. |
| Dersalazine | The risk or severity of adverse effects can be increased when Dersalazine is combined with Methazolamide. |
| Phenyl aminosalicylate | The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Methazolamide. |
| Methyl salicylate | The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Methazolamide. |
| Nitroaspirin | The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Methazolamide. |
| Aloxiprin | The risk or severity of adverse effects can be increased when Aloxiprin is combined with Methazolamide. |
| Guacetisal | The risk or severity of adverse effects can be increased when Guacetisal is combined with Methazolamide. |
| Carbaspirin calcium | The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Methazolamide. |
| Choline salicylate | The risk or severity of adverse effects can be increased when Choline salicylate is combined with Methazolamide. |
| Thiosalicylic acid | The risk or severity of adverse effects can be increased when Thiosalicylic acid is combined with Methazolamide. |
| Phenytoin | The risk or severity of osteomalacia can be increased when Methazolamide is combined with Phenytoin. |
| Fosphenytoin | The risk or severity of osteomalacia can be increased when Methazolamide is combined with Fosphenytoin. |
| Ethoxzolamide | The risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Methazolamide. |
| Acetazolamide | The risk or severity of adverse effects can be increased when Methazolamide is combined with Acetazolamide. |
| Zonisamide | The risk or severity of adverse effects can be increased when Methazolamide is combined with Zonisamide. |
| Diclofenamide | The risk or severity of adverse effects can be increased when Methazolamide is combined with Diclofenamide. |
| Phentermine | Methazolamide may decrease the excretion rate of Phentermine which could result in a higher serum level. |
| Pseudoephedrine | Methazolamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level. |
| Benzphetamine | Methazolamide may decrease the excretion rate of Benzphetamine which could result in a higher serum level. |
| Diethylpropion | Methazolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level. |
| Lisdexamfetamine | Methazolamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. |
| Mephentermine | Methazolamide may decrease the excretion rate of Mephentermine which could result in a higher serum level. |
| MMDA | Methazolamide may decrease the excretion rate of MMDA which could result in a higher serum level. |
| Midomafetamine | Methazolamide may decrease the excretion rate of Midomafetamine which could result in a higher serum level. |